Scholar Rock was cofounded by Boston Children's Hospital researchers Timothy Springer, PhD, and Leonard Zon, MD, in 2014. The biotechnology company is discovering and developing a new class of biologic medicines, called niche activators, which target disease-causing proteins in the tissue microenvironment to achieve therapeutic effects at the source of disease. Scholar Rock is evaluating and pursuing niche modulator drug programs for the treatment of fibrosis, diseases of the musculoskeletal systems and autoimmune diseases.
About our partnership
Scholar Rock has an exclusive license to any intellectual property related to therapeutic applications of niche activators developed by Springer and Zon at their Boston Children's laboratories. (Visit the Springer Lab and Zon Lab for more information.)
Niche modulators are localized actors — protein therapeutics (biologics) — that selectively target particular cell surface and extracellular microenvironments in order to promote or inhibit growth factor activation at sites of disease. This approach to therapies could avoid side effects associated with more general therapies.
Growth factors, which regulate cell growth and differentiation, require "activation" in order to exert their physiological roles. Too much or too little activation of growth factors can be a mechanism that underlies many disease processes.
Scholar Rock secured $20 million in Series A financing in September 2014. Investors include ARCH Venture Partners, Polaris Partners, Timothy Springer, EcoR1 Capital and The Kraft Group. Proceeds from the financing will be used to advance proprietary niche modulators from preclinical research toward clinical drug development.
In the news